Representatives from the National Comprehensive Cancer Network (NCCN), American Society for Clinical Oncology (ASCO), American Society of Hematology (ASH), CDC, FDA, and the authors of the JAMA Oncology article detailing the meeting convened to address the perceived variance among clinical practice guidelines for disease management in patients with cancer and those with sickle cell disease.1 Though there …